
DIA-AID 1 is a phase 3, double blind, placebo-controlled study evaluating the safety and efficacy of DiaPep277 as a treatment for newly diagnosed T1D. The LADA study was a phase 2, randomized, double blind, placebo-controlled, parallel-group clinical trial that also evaluated the safety and how well people tolerated DiaPep277.
In both of these studies, changes in stimulated C-peptide secretion were measured and slowed the autoimmune attack. The gold standard of beta cell health in the midst of an autoimmune attack is C-peptide because it relays the ability of the insulin-producing cells to respond to glucose.
C-peptide is also shown to be the dog in the race to win for treating and reversing many of the complications observed in long-term T1D, including hypoglycemic unawareness, retinopathy, kidney disease, and peripheral neuropathy.
For decades the goal has been to “cure” T1D. That’s still a great plan and I’d love to see it happen in my lifetime. However, in the meantime, I’d love to see a therapy come to fruition that can restore the levels of C-peptide in people with T1D and LADA.
Visit Your Diabetes Health for more resources about health.
Bloggers
Media